Evidence map›Paper›PMID 39845978›Full record

ArticleFrontiers in immunology2024

Identification of an immunological signature of long COVID syndrome.

Gisella Guerrera, Manolo Sambucci, Eleonora Timperi, Mario Picozza, Andrea Misiti, Roberta Placido, Silvia Corbisiero, Silvia D'Orso, Andrea Termine, Carlo Fabrizio and 9 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. CD4Frontiers in immunology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gisella Guerrera *Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Manolo Sambucci *Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Eleonora Timperi *Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Mario PicozzaNeuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Andrea MisitiNeuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Roberta PlacidoNeuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Silvia CorbisieroNeuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Silvia D'OrsoNeuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Andrea TermineData Science Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Carlo FabrizioData Science Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Francesca GarganoNeuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Sharon Eleuteri *Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Luisa MarchioniUOS Terapia Intensiva Postoperatoria e Assistenza Subintensiva, National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy.
Veronica BordoniUnit of Pathogen specific Immunity, Research Area of Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Luigi CoppolaInfectious disease Clinic, Policlinico Tor Vergata of Rome, Rome, Italy.
Marco IannettaDepartment of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, Rome, Italy.
Chiara AgratiUnit of Pathogen specific Immunity, Research Area of Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Giovanna BorsellinoNeuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
Luca BattistiniNeuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Acute COVID-19 infection causes significant alterations in the innate and adaptive immune systems. While most individuals recover naturally, some develop long COVID (LC) syndrome, marked by persistent or new symptoms weeks to months after SARS-CoV-2 infection. Despite its prevalence, there are no clinical tests to distinguish LC patients from those fully recovered. Understanding the immunological basis of LC is essential for improving diagnostic and treatment approaches. Methods: We performed deep immunophenotyping and functional assays to examine the immunological profiles of LC patients, individuals with active COVID-19, recovered patients, and healthy donors. This analysis assessed both innate and adaptive immune features, identifying potential biomarkers for LC syndrome. A Binomial Generalized Linear Model (BGLM) was used to pinpoint immune features characterizing LC. Results: COVID-19 patients exhibited depletion of innate immune cell subsets, including plasmacytoid and conventional dendritic cells, classical, non-classical, and intermediate monocytes, and monocyte-derived inflammatory dendritic cells. Elevated basal inflammation was observed in COVID-19 patients compared to LC patients, whose immune profiles were closer to those of healthy donors and recovered individuals. However, LC patients displayed persistent immune alterations, including reduced T cell subsets (CD4, CD8, Tregs) and switched memory B cells, similar to COVID-19 patients. Through BGLM, a unique adaptive immune signature for LC was identified, featuring memory CD8 and gd T cells with low proliferative capacity and diminished expression of activation and homing receptors. Discussion: The findings highlight a unique immunological signature associated with LC syndrome, characterized by persistent adaptive immune dysregulation. While LC patients displayed recovery in innate immune profiles comparable to healthy and Recovered individuals, deficits in T cell and memory B cell populations were evident, differentiating LC from full recovery. These findings provide insights into LC pathogenesis and may support the development of diagnostic tools and targeted therapies.

Indexed as

COVID-19SARS-CoV-2Adaptive ImmunityAdultAgedBiomarkersDendritic CellsFemaleHumansImmunity, InnateImmunophenotypingMaleMiddle AgedPost-Acute COVID-19 SyndromeBiomarkersimmune dysregulationimmune responseimmunological signatureLong COVIDpost-acute sequelae of COVID19SARS-CoV-2 infection

Identifiers

PMID39845978
PMCPMC11750999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.